Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) Sees Significant Decrease in Short Interest

Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) was the recipient of a large decline in short interest in the month of March. As of March 13th, there was short interest totaling 5,208 shares, a decline of 35.2% from the February 26th total of 8,036 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average trading volume of 17,617 shares, the short-interest ratio is currently 0.3 days.

Barinthus Biotherapeutics Price Performance

Barinthus Biotherapeutics stock opened at $0.55 on Friday. The stock’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.87. Barinthus Biotherapeutics has a 1-year low of $0.51 and a 1-year high of $2.92. The company has a market cap of $22.47 million, a PE ratio of -0.34 and a beta of -0.63.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.13. On average, equities research analysts anticipate that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Barinthus Biotherapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Barinthus Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $4.00.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 115.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 143,100 shares of the company’s stock after buying an additional 76,800 shares during the quarter. Renaissance Technologies LLC owned 0.35% of Barinthus Biotherapeutics worth $100,000 as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by institutional investors and hedge funds.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.